OpGen sets IPO price at $8 to $10 per share

Gaithersburg-based biotech OpGen Inc. could raise as much as $37.5 million in gross proceeds from its initial public offering.

The molecular diagnostics company, which announced plans for an IPO last month, will sell 3.75 million shares with a targeted price range of $8 to $10 per share, it said in a regulatory filing Monday.

It expects net proceeds of $30.5 million.

OpGen has not set a date for the stock offering. It will be managed by Maxim Group LLC.

OpGen will trade on the Nasdaq under the…